Shuttle Pharma Q1 update: FDA clears Phase 2 glioblastoma trial; cash $4.2M

Shuttle Pharmaceuticals Holdings, Inc.

FDA approved Phase 2 trial of Ropidoxuridine for glioblastoma; central IRB approved; first patient dosing expected Q2 2024.
Cash and marketable securities at March 31, 2024 totaled approx. $4.2 million.
Formed new wholly owned subsidiary Shuttle Diagnostics to develop predictive biomarker tests for prostate cancer.
Obtained exclusive licenses from Georgetown University for predictive biomarker program and PSMA-B IP for metastatic prostate cancer.
Finalizing site enrollment at up to six institutions for Phase 2 trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Shuttle Pharmaceuticals Holdings, Inc. reported preliminary financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: preliminary results

Exact text from the filing

On May 14, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), issued a press release providing a corporate update in connection with the filing of our Quarterly Report on Form 10-Q for the period ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.